Trastuzumab gold-conjugates: synthetic approach and in vitro evaluation of anticancer activities in breast cancer cell lines.

Trastuzumab gold-conjugates: synthetic approach and in vitro evaluation of anticancer activities in breast cancer cell lines.

Chem Commun (Camb). 2019 Jan 11;:

Authors: Curado N, Dewaele-Le Roi G, Poty S, Lewis JS, Contel M

Abstract
We describe the preparation of gold(i)-compounds that are amenable to efficient bioconjugation with monoclonal antibodies via activated ester or maleimide linkers. New Trastuzumab-gold conjugates were synthesized and fully characterized. These bioconjugates are significantly more cytotoxic (sub-micromolar range) to HER2-positive breast cancer cells than the gold complexes and Trastuzumab.

PMID: 30632546 [PubMed - as supplied by publisher]

from A via a.sfakia on Inoreader http://bit.ly/2Cl8M54